Unicoat Pharma ApS: Financial statements 2023
CVR: 37166707
Source: annual report 2023, Danish Business Authority
01/01/2023 – 31/12/2023
Unicoat Pharma ApS (CVR 37166707) has filed annual accounts for 2023. In 2023, the company reported a gross profit of DKK 987,760 and a net result of DKK 777,379 compared with DKK 542,284 the year before. That is an increase of 40.2% compared with the year before. Equity in the 2023 report amounted to DKK 577,403. The solvency ratio was 63.9%.
- Gross Profit
- DKK 987,760
- Profit/Loss
- DKK 777,379
- Equity
- DKK 577,403
- Total Assets
- DKK 903,856
Development
| Year | Revenue | Gross Profit | Profit/Loss | Equity | Employees |
|---|---|---|---|---|---|
| 2023 | - | 988 t. | 777 t. | 577 t. | - |
| 2022 | - | 705 t. | 542 t. | 393 t. | - |
| 2021 | - | 689 t. | 535 t. | 290 t. | - |
| 2020 | - | 1.3 mio. | 632 t. | 144 t. | - |
| 2019 | - | 648 t. | 523 t. | 712 t. | - |
Official annual report
Fetch this data via API
Every Danish company, financial statement and ownership record — straight into your own systems or your AI assistant via MCP.
See the API documentationEvents in 2023
Unicoat Pharma ApS has published its annual report for 2022. Gross profit came to DKK 704,509, and the net result was DKK 542,284.
About Unicoat Pharma ApS
Unicoat Pharma ApS is a Danish company of the type Anpartsselskab based in Hillerød, founded in 2015. The company is registered under the industry Overfladebehandling af metal. The management consists of Morten Clausen, Amanda Ryberg and Magnus Knorr Clausen. The company is owned by M C Holding ApS, MCVA Holding ApS and A Ryberg Holding ApS. According to the 2025 annual report, the company had an average of 0 employees. In 2025, the company reported a gross profit of DKK 867,952 and a net result of DKK 680,181 compared with DKK 638,057 the year before. Equity in the 2025 report amounted to DKK 507,241.